KR102589234B1 - 둘라글루티드를 함유하는 조성물 및 사용 방법 - Google Patents

둘라글루티드를 함유하는 조성물 및 사용 방법 Download PDF

Info

Publication number
KR102589234B1
KR102589234B1 KR1020207014456A KR20207014456A KR102589234B1 KR 102589234 B1 KR102589234 B1 KR 102589234B1 KR 1020207014456 A KR1020207014456 A KR 1020207014456A KR 20207014456 A KR20207014456 A KR 20207014456A KR 102589234 B1 KR102589234 B1 KR 102589234B1
Authority
KR
South Korea
Prior art keywords
dulaglutide
dose
once weekly
delete delete
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014456A
Other languages
English (en)
Korean (ko)
Other versions
KR20200076705A (ko
Inventor
데이비드 앤드류 콕스
즈본코 밀리세빅
라이 산 탐
앤드류 고든 워너
데이비드 브래들리 우드워드
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102589234(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Priority to KR1020227035115A priority Critical patent/KR20220146656A/ko
Publication of KR20200076705A publication Critical patent/KR20200076705A/ko
Application granted granted Critical
Publication of KR102589234B1 publication Critical patent/KR102589234B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020207014456A 2017-11-21 2018-11-13 둘라글루티드를 함유하는 조성물 및 사용 방법 Active KR102589234B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227035115A KR20220146656A (ko) 2017-11-21 2018-11-13 둘라글루티드를 함유하는 조성물 및 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
US62/589,244 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227035115A Division KR20220146656A (ko) 2017-11-21 2018-11-13 둘라글루티드를 함유하는 조성물 및 사용 방법

Publications (2)

Publication Number Publication Date
KR20200076705A KR20200076705A (ko) 2020-06-29
KR102589234B1 true KR102589234B1 (ko) 2023-10-16

Family

ID=64572530

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227035115A Ceased KR20220146656A (ko) 2017-11-21 2018-11-13 둘라글루티드를 함유하는 조성물 및 사용 방법
KR1020207014456A Active KR102589234B1 (ko) 2017-11-21 2018-11-13 둘라글루티드를 함유하는 조성물 및 사용 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020227035115A Ceased KR20220146656A (ko) 2017-11-21 2018-11-13 둘라글루티드를 함유하는 조성물 및 사용 방법

Country Status (21)

Country Link
US (2) US11576950B2 (enExample)
EP (1) EP3713593A2 (enExample)
JP (3) JP7221956B2 (enExample)
KR (2) KR20220146656A (enExample)
CN (2) CN120478602A (enExample)
AU (2) AU2018372709B2 (enExample)
BR (1) BR112020007817A2 (enExample)
CL (1) CL2020001252A1 (enExample)
CR (1) CR20200202A (enExample)
DO (1) DOP2020000104A (enExample)
EA (1) EA202090971A1 (enExample)
EC (1) ECSP20026436A (enExample)
IL (1) IL274563B2 (enExample)
JO (1) JOP20200126A1 (enExample)
MA (1) MA50798A (enExample)
MX (1) MX2020005231A (enExample)
PE (1) PE20200847A1 (enExample)
PH (1) PH12020550795A1 (enExample)
SG (1) SG11202003687RA (enExample)
UA (1) UA127588C2 (enExample)
WO (1) WO2019103875A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
AU2021213682B2 (en) * 2020-01-30 2025-05-29 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4153130A1 (en) * 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
CA3223313A1 (en) 2021-06-23 2022-12-29 Eli Lilly And Company Methods of using and compositions including an incretin analog

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009562A2 (en) * 2007-07-10 2009-01-15 Eli Lilly And Company Glp-1-fc fusion protein formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
CN101044162B (zh) 2004-12-22 2010-10-27 伊莱利利公司 Glp-1类似物融合蛋白质制剂
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN110650747A (zh) 2017-06-01 2020-01-03 伊莱利利公司 用于治疗慢性肾病的杜拉鲁肽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009562A2 (en) * 2007-07-10 2009-01-15 Eli Lilly And Company Glp-1-fc fusion protein formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diabetes, Obesity and Metabolism. 13, 426~433, 2011*
Lillian L. Smith, 등, P&T. June 2016, Vol. 41 No. 6, 357~360*

Also Published As

Publication number Publication date
CN111356472A (zh) 2020-06-30
US11576950B2 (en) 2023-02-14
JP2021502379A (ja) 2021-01-28
JOP20200126A1 (ar) 2020-05-21
IL274563A (en) 2020-06-30
US20240189394A1 (en) 2024-06-13
SG11202003687RA (en) 2020-06-29
JP7221956B2 (ja) 2023-02-14
EP3713593A2 (en) 2020-09-30
AU2022203372A1 (en) 2022-06-09
MX2020005231A (es) 2020-08-24
AU2018372709A1 (en) 2020-05-14
ECSP20026436A (es) 2020-06-30
KR20220146656A (ko) 2022-11-01
EA202090971A1 (ru) 2020-08-07
WO2019103875A2 (en) 2019-05-31
CN120478602A (zh) 2025-08-15
PH12020550795A1 (en) 2021-04-19
DOP2020000104A (es) 2020-08-31
IL274563B1 (en) 2023-08-01
NZ763815A (en) 2023-11-24
BR112020007817A2 (pt) 2020-10-06
AU2022203372B2 (en) 2025-04-10
WO2019103875A3 (en) 2019-07-25
UA127588C2 (uk) 2023-10-25
JP2024056908A (ja) 2024-04-23
US20200330558A1 (en) 2020-10-22
CR20200202A (es) 2020-08-20
JP2022062153A (ja) 2022-04-19
PE20200847A1 (es) 2020-08-18
CL2020001252A1 (es) 2020-10-30
MA50798A (fr) 2020-09-30
CA3082625A1 (en) 2019-05-31
AU2018372709B2 (en) 2022-04-28
KR20200076705A (ko) 2020-06-29
IL274563B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
AU2022203372B2 (en) Methods of using and compositions containing dulaglutide
JP2024129139A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP7475398B2 (ja) 医学療法におけるセマグルチド
EP3541366B1 (en) Buffered formulations of exendin (9-39)
KR20210024583A (ko) 요법을 위한 gip/glp1 공효능제 사용 방법
EP2524693B1 (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
CN107496907A (zh) 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品
KR20220132607A (ko) 티르제파티드의 치료 용도
Garber Liraglutide in oral antidiabetic drug combination therapy
US9814729B2 (en) Nerve agent antidotes
KR20250029908A (ko) 티르제파티드 조성물 및 용도
CN113631181A (zh) 度拉糖肽的治疗用途
CA3082625C (en) Methods of using and compositions containing dulaglutide
JP2023510609A (ja) Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法
EA041605B1 (ru) Способы применения и композиции, содержащие дулаглутид
CN114980917A (zh) 杜拉鲁肽的治疗用途
KR20230000682A (ko) 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드
McKeirnan et al. Immunizations and Diabetes
Samuel et al. A Retrospective Comparison Study between the Effectiveness and Safety of Fixed Dose Combination of Vildagliptin versus Sitagliptin with Metformin in Type 2 Diabetes Mellitus Patients
Rosano et al. Hypoglycaemic agents in patients with heart failure
Idris Highlights from the 77th Scientific Sessions of the American Diabetes Association Scientific Meeting, 9-13 June 2017, San Diego, USA.
Gonzalez Brao 48th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany-October 1-5, 2012

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200520

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220603

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220120

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221007

PJ0201 Trial against decision of rejection

Patent event date: 20221007

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220603

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101001836

Request date: 20221007

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101001836; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20221007

Effective date: 20230906

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230906

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20221007

Decision date: 20230906

Appeal identifier: 2022101001836

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20230911

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20230906

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231011

End annual number: 3

Start annual number: 1

PG1601 Publication of registration